RBC puts Adams Respiratory at sector perform

Adams Respiratory Therapeutics Inc. was rated by RBC Capital Markets analyst Ken Trbovich at sector perform, above average risk. The analyst believes the decline in Adams Respiratory's share price was due to speculative buying ahead of the Food and Drug Administration's announcement on unapproved drugs. RBC is confident the company will at some point receive de facto exclusivity for Mucinex-D and Mucinex-DM. Shares of the Chester, N.J.-based pharmaceutical company were down 90 cents, or 1.91%, at $46.16 on volume of 146,231 shares versus the three-month running average of 279,857 shares. (Nasdaq: ARXT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.